{
    "id": 20843,
    "fullName": "ZKSCAN1 - BRAF",
    "impact": "fusion",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "ZKSCAN1-BRAF results from the fusion of ZKSCAN1 and BRAF, which leads to increased cellular invasion, and cell proliferation and phospho-Mek/Erk levels comparable to wild-type Braf in culture (PMID: 30254212), and therefore, is predicted to lead to a gain of protein function. ZKSCAN1-BRAF has been identified in spitzoid melanoma (PMID: 26314551).",
            "references": [
                {
                    "id": 5129,
                    "pubMedId": 26314551,
                    "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26314551"
                },
                {
                    "id": 12368,
                    "pubMedId": 30254212,
                    "title": "BRAF fusions identified in melanomas have variable treatment responses and phenotypes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30254212"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7586,
        "geneSymbol": "ZKSCAN1",
        "terms": [
            "ZKSCAN1",
            "KOX18",
            "PHZ-37",
            "ZNF139",
            "ZNF36",
            "ZSCAN33"
        ]
    },
    "variant": "ZKSCAN1 - BRAF",
    "createDate": "04/08/2016",
    "updateDate": "10/17/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 673,
                "geneSymbol": "BRAF",
                "terms": [
                    "BRAF",
                    "B-raf",
                    "B-RAF1",
                    "BRAF1",
                    "NS7",
                    "RAFB1"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 5661,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with a Spitzoid melanoma harboring ZKSCAN1-BRAF displayed a clinical response within 14 days to treatment with Mekinist (trametinib) (PMID: 26314551).",
            "molecularProfile": {
                "id": 21340,
                "profileName": "ZKSCAN1 - BRAF"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5129,
                    "pubMedId": 26314551,
                    "title": "The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26314551"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21340,
            "profileName": "ZKSCAN1 - BRAF",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}